Skip to main content

Brannan Stephen K.'s Form 4 filing

Karuna Therapeutics, Inc. (KRTX) · filed Aug 11, 2022

Accession no.
0001593968-22-001336
Filed
Aug 11, 2022
Trade date
Aug 9, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $5.70M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Brannan Stephen K.CIK 0001777631Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2022Common StockMOption exerciseAcquired+5,703$7.27+$41,460.8120,703Direct
Aug 9, 2022Common StockSSaleDisposed−5,703$228.10F2−$1,300,854.315,000Direct
Aug 9, 2022Common StockMOption exerciseAcquired+7,033$7.27+$51,129.9122,033Direct
Aug 9, 2022Common StockSSaleDisposed−7,033$228.13−$1,604,438.2915,000Direct
Aug 9, 2022Common StockMOption exerciseAcquired+12,264$9.20+$112,828.827,264Direct
Aug 9, 2022Common StockSSaleDisposed−12,264$228.05F3−$2,796,805.215,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 9, 2022Common StockMOption exerciseDisposed−5,703$0.00$019,143Direct
Aug 9, 2022Common StockMOption exerciseDisposed−7,033$0.00$012,110Direct
Aug 9, 2022Common StockMOption exerciseDisposed−12,264$0.00$022,725Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.06 to $228.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.04 to $228.06, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)